Gossamer announces $230m series B close

The Abu Dhabi Investment Authority has backed the business for the first time.

Gossamer, a US-based biotechnology company that focuses on novel therapeutic products, has this week closed a $230m series B funding round.

First-time investors include the Abu Dhabi Investment Authority, Invus, the Baupost Group and Polaris Partners, while ARCH Venture Partners and Omega Funds have returned.


Supporting articles

Copyright Mawsonia Limited 2010. Please don't cut articles from www.globalgovernmentventuring.com or the PDF and redistribute by email or post to the web without written permission.